NASA Funds DMI for rHEALTH X with Non-Invasive Capabilities

The DNA Medicine Institute (DMI) announced today that it has been awarded a contract from NASA to enhance the rHEALTH platform with non-invasive diagnostic capabilities. The rHEALTH X system leverages cutting-edge technology to measure a wide array of biomarkers from just a single drop of blood, bodily fluid, or other sample.

“We are thrilled to receive this contract from NASA and to expand the rHEALTH technology with non-invasive features,” said Eugene Y. Chan, MD, Principal Investigator of the contract. “Our goal is to create a single, handheld device capable of delivering comprehensive biomedical diagnostics for astronauts aboard the International Space Station and for long-duration missions to Mars and other challenging destinations. Empowering astronauts to autonomously monitor every vital lab measurement is critical to maximizing mission success. We are grateful to NASA for their continued support and this exciting opportunity.”

The contract specifically funds the development of EKG, respiratory rate, SpO2, and temperature measurement capabilities. Integrated with the existing rHEALTH technology, these enhancements will provide astronauts with a complete suite of vital sign monitoring tools—reinforcing DMI’s commitment to advancing space health innovation.